Lv13
80 积分 2024-09-18 加入
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
2小时前
已完结
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy
22小时前
已完结
Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era
1天前
已完结
Advances in the Pathogenesis, Diagnosis, Treatment, and Prognosis of Marginal Zone Lymphoma
2天前
已完结
The biology of marginal zone lymphoma subtypes: challenge and relevance of classification
5天前
已完结
The treatment of marginal zone lymphoma
5天前
已完结
Avoiding Delays in Reporting Time-to-Event Randomized Trials: Calendar Backstops and Other Approaches
26天前
已完结
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors
2个月前
已完结
Long‐term results of Waldenström macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO)
2个月前
已完结
How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia
2个月前
已完结
皖公网安备34019202002308
